| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 1.50 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 | 0.12 | 0.17 | 0.07 |
| Quick Ratio | 1.50 | 0.01 | 0.01 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.01 | 0.12 | 0.17 | 0.07 |
| Debt / Equity | 0.04 | -0.11 | -0.13 | -0.33 | -0.20 | -0.43 | -0.39 | -0.70 | -0.64 | -0.47 | — | — |
| ROE | -423.72% | 48.17% | 85.35% | 87.91% | 78.81% | 130.19% | 133.88% | 104.25% | 144.58% | 366.83% | 111.76% | 58.90% |
| ROA | -300.14% | -2515.76% | -4410.17% | -3255.42% | -18454.29% | -4812.04% | -5664.79% | -9860.56% | -8275.57% | -2482.01% | -544.24% | -729.32% |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | — | — | — |
| Book Value / Share | 3.50 | -0.04 | -1.79 | -44.32 | -1.01 | -14114.05 | — | — | — | — | — | — |
Propanc Biopharma Inc. is a biopharmaceutical company focused on the development of novel cancer treatments. The primary function of the company is to research and develop therapeutic solutions specifically targeting cancerous tumors. Its innovative approach involves proenzyme therapy, which utilizes proenzymes or inactive precursors of enzymes, as a potential solution to treating a variety of cancer types by targeting and inhibiting cancerous cells. The biotechnology sector recognizes Propanc Biopharma for its pioneering work in advancing methods to prevent tumor recurrence and metastasis. The company's efforts target diseases with high unmet medical needs, aiming to improve patient outcomes with fewer side effects compared to conventional treatment options. Propanc Biopharma plays a significant role in the healthcare and life sciences sectors, contributing to the ongoing evolution of cancer treatment strategies. Operating within a competitive and rapidly advancing industry, Propanc Biopharma is a part of the broader movement towards innovative cancer therapies that redefine treatment paradigms and offer hope to patients worldwide.